The Serena-6 trial evaluates whether AZD9833 (an oral SERD) plus CDK4/6 inhibitor is superior to standard therapy in HR+/HER2− advanced breast cancer with a detectable ESR1 mutation prior to progression (NCT04964934). Here, CDK4 is linked to breast cancer.